reports
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incen...
Translate Bio Announces Second Quarter 2021 Financial Results and Prov...
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update -- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease vaccine programs, including Sanofi Pasteur initiation of influenza clinical trial; clinical trial results from two mRNA vaccines anticipated this year -- -- Continued progress in development of mRNA therapeut...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technolog...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development -- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence -- -- Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology -- PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA)...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on July 6, 2021, the Company granted non-qualified stock options to purchase an aggregate of 177,400 shares of the Company’s common stock to nine new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influ...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine -- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial -- -- Interim data anticipated by the end of 2021; outcomes from this clinical trial will inform next steps of our mRNA-based influenza vaccine program and strategy -- LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Sanofi...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on June 7, 2021, the Company granted non-qualified stock options to purchase an aggregate of 238,200 shares of the Company’s common stock to fifteen new employees. These grants were made pursuant to the Company’s 2021 Inducement St...
Translate Bio Achieves Manufacturing Milestone Related to Influenza mR...
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program -- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks -- LEXINGTON, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, toda...
Translate Bio to Participate in Upcoming Investor Conferences
Translate Bio to Participate in Upcoming Investor Conferences LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences: Jefferies Virtual Healthcare Conference: Ronald Renaud, chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on T...
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskines...
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference – Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into IND-enabling studies in 2H 2021 – LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today presented positive results from a preclinical study of a novel mRNA-base...
Translate Bio Announces First Quarter 2021 Financial Results and Provi...
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update -- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year -- -- Reported interim data from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Enhanced internal capabilities across pulmonary programs, manufacturing and financial operations with key leadership additions and promotions -- LEXINGTON, Mass., May 06, 2021 (G...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on May 3, 2021, the Company granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to six new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Inc...
Translate Bio to Present at the 7th Annual Truist Securities Life Scie...
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 10:30 a.m. EST. A live webcast of the session will be accessible through...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on April 19, 2021, the Company granted non-qualified stock options to purchase an aggregate of 201,800 shares of the Company’s common stock to Brendan Smith, the newly hired Chief Financial Officer of Translate Bio. These grants w...
Translate Bio Announces Key Leadership Additions and Promotions
Translate Bio Announces Key Leadership Additions and Promotions -- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary programs, manufacturing and financial operations with a goal of advancing platform, preclinical and clinical milestones -- LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to...
Translate Bio Announces Publication of Preclinical Results of COVID-19...
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines -- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy demonstrated in Syrian Golden Hamster challenge model under single and two-dose vaccination regimens of MRT5500 -- -- MRT5500 developed under a collaboration agreement with Sanofi Pasteur; Phase 1/2 clinical trial underway with clinical data anticipated in the third quarter of 2021 -- L...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on April 5, 2021, the Company granted non-qualified stock options to purchase an aggregate of 111,800 shares of the Company’s common stock to fourteen newly hired employees. These grants were made pursuant to the Company’s 2021 In...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on March 22, 2021, the Company granted non-qualified stock options to purchase an aggregate of 300,000 shares of the Company’s common stock to its newly hired President, Dr. Rand Sutherland. This grant was made pursuant to the Com...
Translate Bio Appoints Dr. Rand Sutherland as President
Translate Bio Appoints Dr. Rand Sutherland as President -- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced that Rand Sutherland, MD, MPH, has been appointed President effective March 22, 2021, Dr. Sutherland's first day of employment. Dr. Sutherland brings 20 years of combined industry, medical and academic expertise in pu...
Translate Bio Announces Results from Second Interim Data Analysis from...
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF) -- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports advancing mRNA therapeutics for pulmonary diseases; additional translational research ongoing to optimize future clinical development of mRNA cystic fibrosis programs, including MRT5005 and a next-generation CF candidate -- -- Company committed to...
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COV...
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate -- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results expected in Q3 2021 -- -- Translate Bio to receive $25 million payment upon initiation of the Phase 1/2 clinical trial -- -- In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants -- PARIS and LEXINGTON, Mass., March 12, 2021 (...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.